FinanceCity
HealthcareNSE · BSE

Concord Biotech Limited

CONCORDBIO · ISIN INE338H01029

Share price

₹1,374 -0.49%

Market capitalisation

₹14369 CrClosed

Live from Yahoo Finance. Pulse animates during NSE market hours (9:15–15:30 IST, weekdays).

01 · Key metrics

Market cap

₹14369 Cr

Current price

₹1,374

-0.49% today

52W high

₹2,111

52W low

₹987

Stock P/E

55.29

P/B ratio

7.15

02 · Per share & returns

EPS (TTM)

₹24.84

Book value

₹192

ROE

13.54%

ROA

8.58%

Dividend yield

0.55%

Beta

0.51

03 · Financials (TTM)

By the numbers

Revenue

₹1055 Cr

-24.10% YoY

EBITDA

₹367 Cr

Net profit

₹261 Cr

-37.00% YoY

Profit margin

24.73%

Operating margin

30.36%

Total debt

₹2.32 Cr

Total cash

₹416 Cr

Debt / equity

0.00x

Current ratio

7.39x

Payout ratio

43.18%

04 · Analyst view

Target price

₹1,196

Upside

-12.92%

Consensus

BUY

Analysts

5

05 · Shareholding pattern

Who owns CONCORDBIO?

  • Promoters

    44.08%

    Founders & promoter group

  • Institutions

    12.54%

    FII + DII

  • Public

    43.38%

    Retail & non-institutional

As of 31 Mar 2026 · Source: NSE corporate filings

06 · Registration & listing

On the record

Symbol
CONCORDBIO
Exchange
NSE · BSE
CIN
ISIN
INE338H01029
BSE code
543960
Sector
Healthcare
Industry
Healthcare
Face value
₹1
Listing date
17 Aug 2023
Employees
Headquarters
Ahmedabad, India

07 · About

What is Concord Biotech Limited?

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

08 · Common questions

Frequently asked

What is the CIN of Concord Biotech Limited?+

The Corporate Identity Number for Concord Biotech Limited is published in the MCA21 corporate master. FinanceCity backfills CIN values during weekly refreshes.

Who are the promoters of Concord Biotech Limited?+

Promoter holding in CONCORDBIO is approximately 44.08%, as disclosed in the latest published shareholding pattern.

What is the market capitalisation of Concord Biotech Limited?+

Concord Biotech Limited (CONCORDBIO) has a market capitalisation of approximately ₹14369 Cr, reflecting the most recent weekly refresh from the BSE scrip master.

09 · Adjacent

Other healthcare listings

Full sector →